Postal Realty Trust, Inc. Reports Fourth Quarter and Year End 2023 Results

Written by Customer Service on February 26, 2024. Posted in Earnings Releases And Operating Results.

– Acquired 75 USPS Properties for $20.7 Million in Fourth Quarter 2023 –– Net Income Attributable to Common Shareholders of $0.12 and Adjusted Funds from Operations of $1.07 Per Diluted Share for the Year Ended 2023 –– Raised Dividend Per Share for Fifth Consecutive Year –– Collected 100% of Contractual Rents – CEDARHURST, N.Y., Feb. 26, 2024 (GLOBE NEWSWIRE) — Postal Realty Trust, Inc. (NYSE: PSTL) (the “Company”), an internally managed real estate investment trust that owns and manages over 1,900 properties leased primarily to the United States Postal Service (the “USPS”), ranging from last-mile post offices to industrial facilities, today announced results for the quarter and year ended December 31, 2023. Highlights for the Quarter Ended December 31, 2023 Acquired 75 USPS properties...

Telix Expands U.S. Development and Manufacturing Infrastructure with Acquisition of IsoTherapeutics

Written by Customer Service on February 26, 2024. Posted in Mergers And Acquisitions.

MELBOURNE, Australia, Feb. 27, 2024 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire IsoTherapeutics Group, LLC (IsoTherapeutics), a specialty radiopharmaceutical development and bioconjugation firm, based in Angleton, Texas. Founded in 2005, IsoTherapeutics is a privately held, commercial-stage company, which provides radiochemistry and bioconjugation development and contract manufacturing services to many companies in the radiopharmaceutical industry, including Telix. In line with Telix’s continued investment in the vertical integration of supply chain, manufacturing and development capabilities, the acquisition is expected to further enhance Telix’s in-house drug development capabilities. A key driver for the acquisition is to enable Telix...

CrossAmerica Partners LP Reports Fourth Quarter and Full Year 2023 Results

Written by Customer Service on February 26, 2024. Posted in Earnings Releases And Operating Results.

Allentown, PA, Feb. 26, 2024 (GLOBE NEWSWIRE) — CrossAmerica Partners LP Reports Fourth Quarter and Full Year 2023 Results Reported Fourth Quarter 2023 Net Income of $16.7 million, Adjusted EBITDA of $47.6 million and Distributable Cash Flow of $35.8 million compared to Fourth Quarter 2022 Net Income of $17.1 million, Adjusted EBITDA of $44.3 million and Distributable Cash Flow of $33.3 million Generated Full Year 2023 Net Income of $42.6 million, Adjusted EBITDA of $165.8 million and Distributable Cash Flow of $116.7 million compared to Full Year 2022 Net Income of $63.7 million, Adjusted EBITDA of $179.8 million and Distributable Cash Flow of $140.9 million Reported Fourth Quarter 2023 Gross Profit for the Wholesale Segment of $33.0 million compared to $32.8 million of Gross Profit for the Fourth Quarter 2022 and Fourth Quarter...

SI-BONE, Inc. Reports Record Fourth Quarter and Full Year 2023 Financial Results and Issues 2024 Guidance

Written by Customer Service on February 26, 2024. Posted in Earnings Releases And Operating Results.

SANTA CLARA, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) — SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 Highlights (all comparisons are to the prior year period) Worldwide revenue of $38.9 million, representing an increase of ~22% U.S. revenue of $36.7 million, representing an increase of ~22% Gross Margin of ~74%, reflecting a ~4 percentage point reduction from excess inventory reserve Over 1,130 active physicians, representing an increase of ~22% Cash and equivalents of ~$166 million, representing net cash usage of ~$0.8 million Fiscal Year 2023 Highlights (all comparisons are to the prior year period) Worldwide revenue of $138.9 million,...

FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results

Written by Customer Service on February 26, 2024. Posted in Earnings Releases And Operating Results.

• Topline data from two pivotal pamrevlumab pancreatic cancer trials anticipated in 2Q 2024 • Additional data from Phase 1 monotherapy study of FG-3246 in metastatic castration-resistant prostate cancer (mCRPC) expected in 1Q 2024 • FibroGen regains rights to roxadustat from AstraZeneca in the United States and other AstraZeneca territories, except China and South Korea • FY 2023 total net revenue of $147.8 million, an increase of 5% year over year • Robust roxadustat volume growth of 41% in China in FY 2023 compared to FY 2022 • Successful execution of cost reduction plan; $248.1 million in cash provides cash runway into 2026 SAN FRANCISCO, Feb. 26, 2024 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the fourth quarter and full year 2023 and provided an update on the company’s recent...

Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress

Written by Customer Service on February 26, 2024. Posted in Earnings Releases And Operating Results.

Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter and full year ended December 31, 2023, and provided an update on corporate progress. The company’s strategic priorities for 2024 are focused on its pioneering RAS(ON) inhibitors: Advancing its RAS(ON) multi-selective inhibitor RMC-6236 into monotherapy pivotal trials. Studies in second line (2L) non-small cell lung cancer (NSCLC) and in 2L pancreatic ductal carcinoma (PDAC) are expected to begin in the second half of 2024. Expanding the reach of RMC-6236 monotherapy and/or combination regimens into earlier lines...

PubMatic Announces Record Fourth Quarter and Fiscal Year Ended 2023 Financial Results; Board of Directors Expands Share Repurchase Program by $100 Million

Written by Customer Service on February 26, 2024. Posted in Earnings Releases And Operating Results.

Q4 2023 revenue and adjusted EBITDA significantly exceeded guidance; Revenue growth accelerated to $84.6 million, up 14% over Q4 2022, delivered net income of $18.7 million or 22% margin, adjusted EBITDA of $38.9 million or 46% margin; Supply Path Optimization represented 45%+ of total activity in Q4 2023; Generated $81.1 million in cash from operations in 2023; Generated $52.8 million in free cash flow in 2023, a 38% increase over 2022 NO-HEADQUARTERS/REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) — PubMatic, Inc. (Nasdaq: PUBM), an independent technology company delivering digital advertising’s supply chain of the future, today reported financial results for the fourth quarter and fiscal year ended December 31, 2023. “We ended 2023 on an incredibly high note, marking an inflection point in revenue growth as we accelerated...

Zoom Video Communications Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Written by Customer Service on February 26, 2024. Posted in Earnings Releases And Operating Results.

Fourth quarter total revenue of $1,146.5 million, up 2.6% year over year as reported and 2.7% in constant currency; full fiscal year total revenue of $4,527.2 million, up 3.1% year over year as reported and 3.8% in constant currency Fourth quarter Enterprise revenue of $667.3 million, up 4.9% year over year; full fiscal year Enterprise revenue of $2,619.3 million, up 8.7% year over year Fourth quarter operating cash flow of $351.2 million, up 66.0% year over year; full fiscal year operating cash flow of $1,598.8 million, up 23.9% year over year; full fiscal year operating cash flow margin of 35.3% Authorization to repurchase up to $1.5 billion of Zoom’s Class A common stock SAN JOSE, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) — Zoom Video Communications, Inc. (NASDAQ: ZM), a platform delivering limitless human connection, today announced...

Asure Announces Fourth Quarter and Full Year 2023 Results

Written by Customer Service on February 26, 2024. Posted in Earnings Releases And Operating Results.

Reports Full Year Revenues of $119.1 million, up 24% from Prior Year Net loss of $9.2 million, an improvement of $5.3 million versus prior year loss of $14.5 million Adjusted EBITDA (1) of $23.3 million, up 97% year over year Management Reiterates 2024 Revenue Guidance of $125.0 million-$129.0 million AUSTIN, Texas, Feb. 26, 2024 (GLOBE NEWSWIRE) — Asure Software, Inc. (“we”, “us”, “our”, “Asure” or the “Company”) (Nasdaq: ASUR), a leading provider of cloud-based Human Capital Management (“HCM”) software solutions, today reported results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights Revenue of $26.3 million, down 10% year over year, excluding ERTC revenue up 15% from prior year Recurring revenue of $25.0 million, up 4% year over year, excluding ERTC recurring revenue up...

EverQuote Announces Fourth Quarter and Full Year 2023 Financial Results

Written by Customer Service on February 26, 2024. Posted in Earnings Releases And Operating Results.

Fourth Quarter Revenue of $55.7 million Fourth Quarter Variable Marketing Margin of $20.7 million Full Year Revenue of $287.9 million Full Year Variable Marketing Margin of $100.3 million CAMBRIDGE, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) — EverQuote, Inc. (Nasdaq: EVER), a leading online insurance marketplace, today announced financial results for the fourth quarter and year ended December 31, 2023. “2023 was a transformative year for EverQuote. We returned to our roots as a capital efficient digital insurance marketplace,” said Jayme Mendal, CEO of EverQuote. “We maintained positive Adjusted EBITDA for the year, improved our balance sheet, and our team managed effectively through historically low carrier demand.” “I am pleased with our outperformance in the fourth quarter, as we exceeded guidance across all three of our primary...

Day: February 26, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice